My current research focuses on the mechanistic understanding of biodistribution and pharmacokinetics, pharmacologic activity and pharmacodynamics, as well as factors that contribute to anti-drug antibody development. Additionally, I am involved in the identification of novel clinical biomarkers for autoimmune and neurodegenerative disorders, and in developing patient stratification strategies. My prior experience includes managing a scientific group engaged in target validation and candidate identification in the areas of autoimmune and female reproductive disorders at Ares Serono (now Merck Serono). As vice president of the translational sciences group at Biogen, I oversee and direct a team of scientists in the development and implementation of bioanalytical and biomarker assays. Using cutting-edge technology platforms, the group develops disease-specific and therapeutic-specific translational biomarkers to delineate the PK/PD as well as the safety and efficacy of therapeutics.